Media events and presentations
This section features resources from sanofi-aventis events at major European and international medical conferences.
You can access webcasts of press conferences, investigator interviews and speaker biographies grouped under the relevant medical congress. Please click below to access the latest medical meetings.
This section features resources from sanofi-aventis events at major European and international medical conferences.
You can access webcasts of press conferences, investigator interviews and speaker biographies grouped under the relevant medical congress. Please click below to access the latest medical meetings.
November 14 - 18, 2009
Orlando, USA
September 01, 2009
New insights from the ATHENA Trial into the effects of dronedarone on hospitalizations and on coronary heart disease in patients with atrial fibrillation were presented at the ESC congress 2009. After the hotline session a media briefing was organised by sanofi-aventis.
During the media briefing an overview of atrial fibrillation and the burden it presents for patients was presented by Professor Camm, St George’s University Hospital, London, including effective prevention of risk factors, systemic strokei prevention, the prevention of AF-related morbidity and mortality, new options for outpatient care and novel approached to therapies. Professor Dorian, St Michaels’ University Hospital, Toronto discussed current perspectives in the management of atrial fibrillation and the “outcomes focussed” approach taken in the ATHENA Trial. Professor Hohnloser, J.W Goethe University Hospital, Frankfurt presented the ATHENA Trial and the latest post-hoc analysis results on AF and non-AF-related hospitalizations and coronary heart disease in patients with atrial fibrillation.
Media briefing Agenda
09h00 : Welcome and Introductions Tony Campion - Facilitator
09h05 : Atrial Fibrillation (AF)i: The underestimated impact of a complex heart disease
• A complex and progressive disease
• An unwanted burden for patients and families: “Living in the shadow of AF”
• Medical and socio-economic impact: the tip of the iceberg Prof. Camm St George’s Hospital, University of London United Kingdom
09h25 : Addressing treatment goals in atrial fibrillation
• Beyond rhythm and rate: perspectives on the management of atrial fibrillation
• A different approach: introduction to dronedarone (Multaq®)
• DAFNE to ATHENA: the evidence for dronedarone in atrial fibrillation Prof. DorianSt Michael’s Hospital, University of Toronto Canada
09h40 : Learnings from the ATHENA Landmark Study in atrial fibrillation
• From symptom management to patient benefit
• Latest post-hoc results Prof. Hohnloser, J. W. Goethe, University, Frankfurt, Germany
09h50 : Panel Discussion and Q&A Session Panel
10h00 : Close Facilitator.
During the media briefing an overview of atrial fibrillation and the burden it presents for patients was presented by Professor Camm, St George’s University Hospital, London, including effective prevention of risk factors, systemic strokei prevention, the prevention of AF-related morbidity and mortality, new options for outpatient care and novel approached to therapies. Professor Dorian, St Michaels’ University Hospital, Toronto discussed current perspectives in the management of atrial fibrillation and the “outcomes focussed” approach taken in the ATHENA Trial. Professor Hohnloser, J.W Goethe University Hospital, Frankfurt presented the ATHENA Trial and the latest post-hoc analysis results on AF and non-AF-related hospitalizations and coronary heart disease in patients with atrial fibrillation.
Media briefing Agenda
09h00 : Welcome and Introductions Tony Campion - Facilitator
09h05 : Atrial Fibrillation (AF)i: The underestimated impact of a complex heart disease
• A complex and progressive disease
• An unwanted burden for patients and families: “Living in the shadow of AF”
• Medical and socio-economic impact: the tip of the iceberg Prof. Camm St George’s Hospital, University of London United Kingdom
09h25 : Addressing treatment goals in atrial fibrillation
• Beyond rhythm and rate: perspectives on the management of atrial fibrillation
• A different approach: introduction to dronedarone (Multaq®)
• DAFNE to ATHENA: the evidence for dronedarone in atrial fibrillation Prof. DorianSt Michael’s Hospital, University of Toronto Canada
09h40 : Learnings from the ATHENA Landmark Study in atrial fibrillation
• From symptom management to patient benefit
• Latest post-hoc results Prof. Hohnloser, J. W. Goethe, University, Frankfurt, Germany
09h50 : Panel Discussion and Q&A Session Panel
10h00 : Close Facilitator.
May 26 - 29, 2009
Data on strokei from the ATHENA trial were presented on Wednesday 27th during the Oral Session “The effect of dronedarone on stroke in patients with atrial fibrillation: Results of ATHENA”. This scientific presentation was given by an Investigator on behalf of the ATHENA Steering Committee: C.Torp-Pedersen, Gentofte Hospital, University of Copenhagen, Dep. of Cardiology, Hellerup, DENMARK.
Background: Many patients with atrial fibrillation (AF)i are at high risk for stroke. Antiarrhythmic drugs have not previously been shown to reduce the risk of stroke in AF. The effect of dronedarone, a new multi-channel blocking antiarrhythmic drug, on stroke has been evaluated in a randomized double-blind clinical trial, ATHENA.
Background: Many patients with atrial fibrillation (AF)i are at high risk for stroke. Antiarrhythmic drugs have not previously been shown to reduce the risk of stroke in AF. The effect of dronedarone, a new multi-channel blocking antiarrhythmic drug, on stroke has been evaluated in a randomized double-blind clinical trial, ATHENA.
May 13 - 16, 2009
Boston, USA
New data from the ATHENA trial were presented on Friday May 15th during the Late-Breaking Clinical Trials II of the Heart and Rhythm Society congress 2009. “Effects of dronedarone on clinical outcomes in patients with atrial fibrillation and congestive heart failurei: insights from ATHENA”. This scientific presentation was given by the Principal Investigator on behalf of the ATHENA Steering Committee: Stefan H. Hohnloser, Division of Clinical Electrophysiology J. W. Goethe University Hospital, Frankfurt, Germany.
New data from the ATHENA trial were presented on Friday May 15th during the Late-Breaking Clinical Trials II of the Heart and Rhythm Society congress 2009. “Effects of dronedarone on clinical outcomes in patients with atrial fibrillation and congestive heart failurei: insights from ATHENA”. This scientific presentation was given by the Principal Investigator on behalf of the ATHENA Steering Committee: Stefan H. Hohnloser, Division of Clinical Electrophysiology J. W. Goethe University Hospital, Frankfurt, Germany.
Latest videos
The True Cost of Atrial Fibrillation
